Literature DB >> 2121674

Susceptibility of NB-I neuroblastoma cells to tumoricidal activity of monocytes activated by gamma-interferon.

H Shimizu1, T Fujimoto.   

Abstract

The purpose of this study was to examine the susceptibility of NB-I human neuroblastoma cells to direct cellular cytotoxicity mediated by peripheral blood monocytes from pediatric cancer patients receiving chemotherapy. Nonactivated monocytes from patients showed spontaneous cytotoxicity to NB-I neuroblastoma cells (37 +/- 18%) but only marginal cytotoxicity to A375 melanoma cells (21 +/- 14%) at the effector:target cell ratio of 20:1. This spontaneous cytotoxicity to NB-I cells was observed only after greater than 24 h of cocultivation and was proportional to the effector:target cell ratio. Activation of monocytes by recombinant human interferon gamma (rIFN) (1 x 10(4) U/ml) consistently and strongly enhanced their tumoricidal activity to NB-I cells (87 +/- 6%) and this tumoricidal activity was even superior to that observed against A375 cells, which are known to be extremely sensitive to lysis by activated monocytes. In contrast, activation of monocytes by lipopolysaccharide (LPS, 1 microgram/ml) had no effect on monocyte-mediated lysis of NB-I cells, while A375 cells were equally lysed by rIFN- and LPS-activated monocytes, thus suggesting that different mechanisms are involved in the monocyte-mediated lysis of A375 melanoma and NB-I neuroblastoma cells. Susceptibility of the neuroblastoma cell line to monocyte-mediated cytotoxicity has not been reported so far and our results may have some clinical implication if this observation can be extended to other neuroblastoma cell lines as well.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2121674      PMCID: PMC5917963          DOI: 10.1111/j.1349-7006.1990.tb03340.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  16 in total

1.  Tumoricidal activity of human monocytes: evidence for cytolytic function distinct from that of NK cells.

Authors:  E S Kleinerman; R B Herberman
Journal:  J Immunol       Date:  1984-07       Impact factor: 5.422

2.  The effects of gamma interferon on the natural killer and tumor cells of children with neuroblastoma. A preliminary report.

Authors:  A Evans; E Main; K Zier; N Ikegaki; M Tartaglione; R Kennett; L Lampson
Journal:  Cancer       Date:  1989-10-01       Impact factor: 6.860

3.  Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant interferon-gamma.

Authors:  W Aulitzky; G Gastl; W E Aulitzky; M Herold; J Kemmler; B Mull; J Frick; C Huber
Journal:  J Clin Oncol       Date:  1989-12       Impact factor: 44.544

4.  Human interleukin 1 is a cytocidal factor for several tumor cell lines.

Authors:  K Onozaki; K Matsushima; B B Aggarwal; J J Oppenheim
Journal:  J Immunol       Date:  1985-12       Impact factor: 5.422

5.  In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors.

Authors:  D J Giard; S A Aaronson; G J Todaro; P Arnstein; J H Kersey; H Dosik; W P Parks
Journal:  J Natl Cancer Inst       Date:  1973-11       Impact factor: 13.506

6.  Human neuroblastoma cell lines are susceptible to lysis by natural killer cells but not by cytotoxic T lymphocytes.

Authors:  E K Main; L A Lampson; M K Hart; J Kornbluth; D B Wilson
Journal:  J Immunol       Date:  1985-07       Impact factor: 5.422

7.  Pharmacokinetics, single-dose tolerance, and biological activity of recombinant gamma-interferon in cancer patients.

Authors:  R Kurzrock; M G Rosenblum; S A Sherwin; A Rios; M Talpaz; J R Quesada; J U Gutterman
Journal:  Cancer Res       Date:  1985-06       Impact factor: 12.701

8.  Tumor necrosis factor: a potent effector molecule for tumor cell killing by activated macrophages.

Authors:  J L Urban; H M Shepard; J L Rothstein; B J Sugarman; H Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

9.  Tumoricidal activity of human monocytes activated in vitro by free and liposome-encapsulated human lymphokines.

Authors:  E S Kleinerman; A J Schroit; W E Fogler; I J Fidler
Journal:  J Clin Invest       Date:  1983-07       Impact factor: 14.808

10.  Effect of recombinant granulocyte/macrophage colony-stimulating factor on human monocyte activity in vitro and following intravenous administration.

Authors:  E S Kleinerman; R D Knowles; L B Lachman; J U Gutterman
Journal:  Cancer Res       Date:  1988-05-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.